Date: 2016-06-17
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at ASM Microbe 2016 in Boston
Company: Arsanis (USA - MA)
Product: ASN200 program including ASN-4
Action
mechanism: monoclonal antibody
Disease: multi-drug resistant Escherichia coli infection
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On June 17, 2016, Arsanis, a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, presented data from two of its preclinical programs demonstrating targeted protection in animal models against certain strains of Escherichia coli (“Efficacy of Therapeutic Monoclonal Antibodies against Multi-Drug Resistant Escherichia coli ST131”) and Klebsiella pneumoniae (“Monoclonal Antibodies Targeting the Conserved LPS O-Antigen of Klebsiella pneumoniae ST258 Elicit Protection”). Within its ASN200 program, Arsanis’ mAb, ASN-4, with high affinity to a specific antigen, O25b, expressed by multidrug-resistant E. coli, was shown to be directly bactericidal, anti-inflammatory and protective at very low concentrations. In the ASN300 program, humanized mAbs to D-galactan III, a conserved antigen of the carbapenem-resistant K. pneumoniae clone, ST258, were protective against systemic infection. The data were presented in a poster session at ASM Microbe 2016 in Boston. Arsanis’ programs aim to address serious infections, such as pneumonia and blood stream infections. The E. coli clone ST131-O25b:H4 targeted by ASN200 causes a significant proportion of multidrug-resistant extra-intestinal infections worldwide. K. pneumoniae, a Gram-negative bacterium with enormous potential to develop antibiotic resistance, is responsible for serious healthcare-associated infections. The ASN200 and ASN300 programs are set to enter preclinical development in 2016. Arsanis is poised to initiate a Phase 2 clinical study in the second half of 2016 with its lead candidate, ASN100, for the prevention of serious Staphylococcus aureus pneumonia.
